Lonza Group
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The last earnings update was 104 days ago. More info.
Add to Portfolio Compare Print
LONN Share Price and Events
7 Day Returns
1 Year Returns
LONN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Lonza Group (LONN) | -0.5% | 7.8% | 12.6% | 23.6% | 107.6% | 249.9% |
| Europe Life Sciences | 2.7% | 2.5% | 10.4% | 21.3% | 84.6% | 204.2% |
| CH Market | 1.3% | 2.9% | 3.1% | 9.8% | 18.7% | 13.6% |
1 Year Return vs Industry and Market
- LONN outperformed the Life Sciences industry which returned 21.3% over the past year.
- LONN outperformed the Market in Switzerland which returned 9.8% over the past year.
Value
Is Lonza Group undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Lonza Group
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Lonza Group.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 13 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.7% |
| Perpetual Growth Rate | 10-Year CH Government Bond Rate | 3.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CH Govt Bond Rate | 3.3% |
| Equity Risk Premium | S&P Global | 6% |
| Life Sciences Unlevered Beta | Simply Wall St/ S&P Global | 0.99 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.99 (1 + (1- 18%) (16.59%)) |
1.084 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.08 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (1.084 * 5.96%) |
9.73% |
Discounted Cash Flow Calculation for SWX:LONN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Lonza Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (CHF, Millions) | Source |
Present Value Discounted (@ 9.73%) |
|
|---|---|---|---|
| 2019 | 505.82 | Analyst x5 | 460.95 |
| 2020 | 718.07 | Analyst x7 | 596.34 |
| 2021 | 829.04 | Analyst x5 | 627.43 |
| 2022 | 921.50 | Analyst x1 | 635.54 |
| 2023 | 998.74 | Est @ 8.38% | 627.72 |
| 2024 | 1,067.15 | Est @ 6.85% | 611.22 |
| 2025 | 1,128.81 | Est @ 5.78% | 589.19 |
| 2026 | 1,185.55 | Est @ 5.03% | 563.92 |
| 2027 | 1,238.91 | Est @ 4.5% | 537.03 |
| 2028 | 1,290.12 | Est @ 4.13% | 509.63 |
| Present value of next 10 years cash flows | CHF5,758.96 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= CHF1,290.12 × (1 + 3.28%) ÷ (9.73% – 3.28%) |
CHF20,630.83 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= CHF20,630.83 ÷ (1 + 9.73%)10 |
CHF8,149.64 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= CHF5,758.96 + CHF8,149.64 |
CHF13,908.60 |
| Equity Value per Share (CHF) |
= Total value / Shares Outstanding
= CHF13,908.60 / 74.25 |
CHF187.33 |
| Calculation | Result | |
|---|---|---|
| Value per share (CHF) | From above. | CHF187.33 |
| Current discount | Discount to share price of
CHF334.70
= -1 x (CHF334.70 - CHF187.33) / CHF187.33 |
-78.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Lonza Group is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Lonza Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Lonza Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in CHF | CHF8.80 |
| SWX:LONN Share Price ** | SWX (2019-06-19) in CHF | CHF334.7 |
| Europe Life Sciences Industry PE Ratio | Median Figure of 16 Publicly-Listed Life Sciences Companies | 37.98x |
| Switzerland Market PE Ratio | Median Figure of 174 Publicly-Listed Companies | 18.47x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Lonza Group.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = SWX:LONN Share Price ÷ EPS (both in CHF) = 334.7 ÷ 8.80 |
38.02x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lonza Group is overvalued based on earnings compared to the Europe Life Sciences industry average.
- Lonza Group is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does
Lonza Group's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 38.02x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts |
14.5%per year |
| Europe Life Sciences Industry PEG Ratio | Median Figure of 12 Publicly-Listed Life Sciences Companies | 2.7x |
| Switzerland Market PEG Ratio | Median Figure of 125 Publicly-Listed Companies | 2.19x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 38.02x ÷ 14.5% |
2.63x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lonza Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Lonza Group's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in CHF | CHF83.75 |
| SWX:LONN Share Price * | SWX (2019-06-19) in CHF | CHF334.7 |
| Europe Life Sciences Industry PB Ratio | Median Figure of 35 Publicly-Listed Life Sciences Companies | 2.5x |
| Switzerland Market PB Ratio | Median Figure of 215 Publicly-Listed Companies | 1.68x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = SWX:LONN Share Price ÷ Book Value per Share (both in CHF) = 334.7 ÷ 83.75 |
4x |
* Primary Listing of Lonza Group.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lonza Group is overvalued based on assets compared to the Europe Life Sciences industry average.
Value checks
We assess Lonza Group's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check) Lonza Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Lonza Group expected to perform in the next 1 to 3 years based on estimates from 13 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Lonza Group's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
- Lonza Group's earnings growth is expected to exceed the Switzerland market average.
- Lonza Group's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| SWX:LONN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts | 14.5% |
| SWX:LONN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts | 7% |
| Europe Life Sciences Industry Earnings Growth Rate | Market Cap Weighted Average | 14.8% |
| Europe Life Sciences Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| Switzerland Market Earnings Growth Rate | Market Cap Weighted Average | 10.9% |
| Switzerland Market Revenue Growth Rate | Market Cap Weighted Average | 3.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CHF Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 7,968 | 2,081 | 1,510 | 4 |
| 2022-12-31 | 7,385 | 1,813 | 1,265 | 6 |
| 2021-12-31 | 6,786 | 1,594 | 1,065 | 10 |
| 2020-12-31 | 6,333 | 1,434 | 922 | 13 |
| 2019-12-31 | 5,930 | 1,249 | 828 | 13 |
| Date (Data in CHF Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 5,542 | 1,082 | 655 |
| 2018-06-30 | 5,874 | 882 | 902 |
| 2018-03-31 | 5,490 | 873 | 814 |
| 2017-12-31 | 4,548 | 841 | 664 |
| 2017-09-30 | 4,758 | 798 | 527 |
| 2017-06-30 | 4,423 | 738 | 334 |
| 2017-03-31 | 4,278 | 745 | 318 |
| 2016-12-31 | 4,132 | 752 | 301 |
| 2016-09-30 | 4,025 | 779 | 331 |
| 2016-06-30 | 3,918 | 805 | 360 |
| 2016-03-31 | 3,861 | 773 | 319 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
All data from Lonza Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CHF Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 19.41 | 20.61 | 18.48 | 3.00 |
| 2022-12-31 | 16.68 | 17.92 | 14.65 | 5.00 |
| 2021-12-31 | 14.17 | 15.11 | 13.30 | 9.00 |
| 2020-12-31 | 12.24 | 13.64 | 11.33 | 11.00 |
| 2019-12-31 | 10.98 | 14.82 | 9.72 | 11.00 |
| Date (Data in CHF Millions) | EPS * |
|---|---|
| 2018-12-31 | 8.80 |
| 2018-06-30 | 12.12 |
| 2018-03-31 | 11.44 |
| 2017-12-31 | 9.78 |
| 2017-09-30 | 7.10 |
| 2017-06-30 | 5.86 |
| 2017-03-31 | 5.17 |
| 2016-12-31 | 5.73 |
| 2016-09-30 | 6.26 |
| 2016-06-30 | 6.88 |
| 2016-03-31 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Lonza Group's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Lonza Group has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Lonza Group performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Lonza Group has delivered over 20% year on year earnings growth in the past 5 years.
- Lonza Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Lonza Group's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.
Earnings and Revenue History
All data from Lonza Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CHF Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 5,542.00 | 655.00 | 1,022.00 | 110.00 |
| 2018-06-30 | 5,874.00 | 902.00 | 1,111.00 | 103.00 |
| 2018-03-31 | 5,489.50 | 814.00 | 1,030.00 | 103.00 |
| 2017-12-31 | 4,548.00 | 664.00 | 831.00 | 95.00 |
| 2017-09-30 | 4,757.50 | 527.00 | 891.00 | 93.50 |
| 2017-06-30 | 4,423.00 | 334.00 | 833.00 | 84.00 |
| 2017-03-31 | 4,277.50 | 317.50 | 782.50 | 84.00 |
| 2016-12-31 | 4,132.00 | 301.00 | 732.00 | 84.00 |
| 2016-09-30 | 4,025.00 | 330.50 | 671.50 | 93.50 |
| 2016-06-30 | 3,918.00 | 360.00 | 611.00 | 103.00 |
| 2016-03-31 | 3,860.50 | 318.50 | 573.50 | 103.00 |
| 2015-12-31 | 3,803.00 | 277.00 | 536.00 | 103.00 |
| 2015-09-30 | 3,773.50 | 242.50 | 528.50 | 102.00 |
| 2015-06-30 | 3,744.00 | 208.00 | 521.00 | 101.00 |
| 2015-03-31 | 3,692.00 | 222.50 | 520.00 | 101.00 |
| 2014-12-31 | 3,640.00 | 237.00 | 519.00 | 101.00 |
| 2014-09-30 | 3,640.00 | 211.50 | 489.50 | 105.50 |
| 2014-06-30 | 3,640.00 | 186.00 | 460.00 | 110.00 |
| 2014-03-31 | 3,612.00 | 136.50 | 444.50 | 110.00 |
| 2013-12-31 | 3,584.00 | 87.00 | 429.00 | 110.00 |
| 2013-09-30 | 3,644.50 | 109.00 | 622.50 | 113.00 |
| 2013-06-30 | 3,705.00 | 131.00 | 816.00 | 116.00 |
| 2013-03-31 | 3,815.00 | 152.50 | 668.00 | 116.00 |
| 2012-12-31 | 3,925.00 | 174.00 | 520.00 | 116.00 |
| 2012-09-30 | 3,694.00 | 156.00 | 430.50 | 105.00 |
| 2012-06-30 | 3,463.00 | 140.00 | 324.00 | 94.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Lonza Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Lonza Group used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
- Lonza Group's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Lonza Group's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Lonza Group has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Lonza Group's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Lonza Group's finances.
The net worth of a company is the difference between its assets and liabilities.
- Lonza Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Lonza Group's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Lonza Group Company Filings, last reported 5 months ago.
| Date (Data in CHF Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 6,290.00 | 4,122.00 | 478.00 |
| 2018-06-30 | 6,407.00 | 4,219.00 | 488.00 |
| 2018-03-31 | 6,407.00 | 4,219.00 | 488.00 |
| 2017-12-31 | 6,181.00 | 4,326.00 | 487.00 |
| 2017-09-30 | 6,253.00 | 4,326.00 | 487.00 |
| 2017-06-30 | 5,311.00 | 1,716.00 | 3,187.00 |
| 2017-03-31 | 5,311.00 | 1,716.00 | 3,187.00 |
| 2016-12-31 | 2,355.00 | 1,917.00 | 286.00 |
| 2016-09-30 | 2,355.00 | 1,917.00 | 286.00 |
| 2016-06-30 | 2,052.00 | 1,763.00 | 257.00 |
| 2016-03-31 | 2,052.00 | 1,763.00 | 257.00 |
| 2015-12-31 | 2,135.00 | 1,987.00 | 280.00 |
| 2015-09-30 | 2,135.00 | 1,987.00 | 280.00 |
| 2015-06-30 | 1,959.00 | 2,067.00 | 224.00 |
| 2015-03-31 | 1,959.00 | 2,067.00 | 224.00 |
| 2014-12-31 | 2,130.00 | 2,296.00 | 218.00 |
| 2014-09-30 | 2,130.00 | 2,296.00 | 218.00 |
| 2014-06-30 | 2,078.00 | 2,460.00 | 275.00 |
| 2014-03-31 | 2,078.00 | 2,460.00 | 275.00 |
| 2013-12-31 | 2,126.00 | 2,522.00 | 332.00 |
| 2013-09-30 | 2,126.00 | 2,522.00 | 332.00 |
| 2013-06-30 | 2,146.00 | 2,790.00 | 275.00 |
| 2013-03-31 | 2,146.00 | 2,790.00 | 275.00 |
| 2012-12-31 | 2,102.00 | 2,865.00 | 439.00 |
| 2012-09-30 | 2,406.00 | 2,865.00 | 429.00 |
| 2012-06-30 | 2,352.00 | 2,888.00 | 278.00 |
- Lonza Group's level of debt (65.5%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (118.6% vs 65.5% today).
- Debt is well covered by operating cash flow (26.2%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 9.8x coverage).
Financial health checks
We assess Lonza Group's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Lonza Group has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Lonza Group's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CHF2,000 of
Lonza Group
shares you are expected to receive
CHF16
in your first year as a dividend.
Dividend Amount
- Lonza Group's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (1.98%).
- Lonza Group's dividend is below the markets top 25% of dividend payers in Switzerland (3.67%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 13 Analyst Estimates (S&P Global) | See Below |
| Europe Life Sciences Industry Average Dividend Yield | Market Cap Weighted Average of 11 Stocks | 0.8% |
| Switzerland Market Average Dividend Yield | Market Cap Weighted Average of 166 Stocks | 3% |
| Switzerland Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Switzerland Bottom 25% Dividend Yield | 25th Percentile | 2% |
| Switzerland Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in CHF) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | 5.33 | 2.00 |
| 2022-12-31 | 4.23 | 4.00 |
| 2021-12-31 | 3.47 | 11.00 |
| 2020-12-31 | 3.16 | 14.00 |
| 2019-12-31 | 2.91 | 14.00 |
| Date (Data in CHF) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-03-07 | 2.750 | 0.890 |
| 2018-02-07 | 2.750 | 0.991 |
| 2017-04-25 | 2.750 | 1.168 |
| 2016-03-16 | 2.500 | 1.418 |
| 2015-02-26 | 2.500 | 1.810 |
| 2015-01-21 | 2.500 | 2.313 |
| 2014-04-17 | 2.150 | 2.094 |
| 2013-04-10 | 2.150 | 2.767 |
| 2012-04-03 | 2.150 | 4.651 |
| 2011-03-04 | 2.150 | 3.688 |
| 2011-01-17 | 2.150 | 2.827 |
| 2010-01-28 | 1.750 | 2.167 |
| 2010-01-04 | 1.750 | 2.208 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lonza Group is not paying a notable dividend for Switzerland, therefore no need to check if the payments are stable.
- Lonza Group is not paying a notable dividend for Switzerland, therefore no need to check if the payments are increasing.
Income/ dividend checks
We assess Lonza Group's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Lonza Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Lonza Group has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| AGE | 58 |
| TENURE AS CEO | 0.3 years |
CEO Bio
Mr. Marc Funk serves as Chief Executive Officer at Lonza Group Ltd since March 01, 2019. Mr. Funk had been the Chief Operating Officer of Pharma & Biotech Market Segment at Lonza Group Ltd (known as Lonza Group AG) since May 2014 till March 01, 2019, served as its Chief Legal Officer since April 2012, and served as its Secretary. Mr. Funk served as Group General Counsel and Board Secretary at Lonza Group Ltd., from 2009 to 2014. He joined Lonza in January 2009. He served as an Associate General Counsel at Merck Serono (formerly Serono) from 2004 to 2008. He served as CO-CEO and General Counsel of GeneProt from 2000 to 2004. He holds a Master of Law from the University of Geneva and a Master of Law and Diplomacy from the Fletcher School (Tuft University MA).
CEO Compensation
- Insufficient data for Marc to compare compensation growth.
- Insufficient data for Marc to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure
Average tenure and age of the Lonza Group management team in years:
- The average tenure for the Lonza Group management team is less than 2 years, this suggests a new team.
Management Team
Marc Funk
Chief Executive Officer
58
0.3 yrs
Rodolfo Savitzky
Chief Financial Officer
56
2.7 yrs
Dirk Oehlers
Head of Investor Relations
Dominik Werner
Head of Corporate Communications & VP
8.8 yrs
Joseph Colleluori
Senior Vice President of Corporate Development
13.4 yrs
Jennifer Clancy
Senior Director of Global Marketing
1.2 yrs
Richard Ridinger
CHF5M
60
0.3 yrs
Constance Ward
Head of External Communications
Sven Abend
Chief Operating Officer of Specialty Ingredients Segment
50
4.9 yrs
Stefan Stoffel
Chief Operating Officer of Lonza Pharma Biotech & Nutrition
0.3 yrs
Board of Directors Tenure
Average tenure and age of the Lonza Group board of directors in years:
- The tenure for the Lonza Group board of directors is about average.
Board of Directors
Albert Baehny
Chairman of the Board
CHF548K
66
1.1 yrs
Patrick Aebischer
Vice Chairman of the Board
CHF293K
64
5.2 yrs
Margot Scheltema
Independent Director
CHF279K
64
7.2 yrs
Christoph Mäder
Independent Director
CHF282K
59
3.2 yrs
Werner Bauer
Independent Director
CHF250K
68
6.2 yrs
Barbara Richmond
Independent Non-Executive Director
CHF271K
58
5.2 yrs
Jürgen Steinemann
Independent Director
CHF240K
60
5.2 yrs
Angelic Kohlmann
Independent Director
CHF188K
58
1.1 yrs
Olivier Verscheure
Independent Director
CHF188K
46
1.1 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CHF) | Value (CHF) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Lonza Group's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Lonza Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
How Lonza Group Ltd's (VTX:LONN) Earnings Growth Stacks Up Against The Industry
View our latest analysis for Lonza Group How Did LONN's Recent Performance Stack Up Against Its Past? … Furthermore, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 36%, indicating the rate at which LONN is growing has slowed down. … I recommend you continue to research Lonza Group to get a better picture of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for LONN’s future growth?
Simply Wall St - – Full articleTaking A Look At Lonza Group Ltd's (VTX:LONN) ROE
The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Lonza Group: 10% = CHF655m ÷ CHF6.3b (Based on the trailing twelve months to December 2018.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … Does Lonza Group Have A Good Return On Equity? … Combining Lonza Group's Debt And Its 10% Return On Equity Although Lonza Group does use debt, its debt to equity ratio of 0.66 is still low.
Simply Wall St - – Full articleLonza Group Ltd (VTX:LONN): Is Growth Priced In?
SWX:LONN Price Estimation Relative to Market, May 20th 2019 Lonza Group's price-to-earnings ratio stands at 36.03x, which is low, relative to the industry average. … But, since Lonza Group is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio. … A PE ratio of 36.03x and expected year-on-year earnings growth of 14% give Lonza Group a quite high PEG ratio of 2.61x.
Simply Wall St - – Full articleWhat Should We Expect From Lonza Group Ltd's (VTX:LONN) Earnings In The Year Ahead?
Help shape the future of investing tools and you could win a $250 gift card! … Based on Lonza Group Ltd's (VTX:LONN) earnings update in December 2018, … analyst consensus outlook appear cautiously optimistic,
Simply Wall St - – Full articleHow Financially Strong Is Lonza Group Ltd (VTX:LONN)?
There are a number of reasons that attract investors towards large-cap companies such as Lonza Group Ltd (VTX:LONN), with a market cap of CHF22b. … I will provide an overview of Lonza Group’s financial liquidity and leverage to give you an idea of Lonza Group’s position to take advantage of potential acquisitions or comfortably endure future downturns. … Note that this information is centred entirely on financial health and is a high-level overview, so I encourage you to look further
Simply Wall St - – Full articleHow Do Analysts See Lonza Group Ltd (VTX:LONN) Performing In The Next Couple Of Years?
The most recent earnings release Lonza Group Ltd's (VTX:LONN) announced in December 2018a
Simply Wall St - – Full articleLonza Group (VTX:LONN) Shareholders Have Enjoyed An Impressive 240% Share Price Gain
But on a lighter note, a good company can see its share price rise well over 100%. … One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. … Over half a decade, Lonza Group managed to grow its earnings per share at 39% a year.
Simply Wall St - – Full articleIs Lonza Group Ltd (VTX:LONN) Potentially Undervalued?
led the SWX gainers with a relatively large price hike in the past couple of weeks. … As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock … However, could the stock still be trading at a relatively cheap price?
Simply Wall St - – Full articleHow Much Of Lonza Group Ltd (VTX:LONN) Do Institutions Own?
If you want to know who really controls Lonza Group Ltd (VTX:LONN), then you'll have to look at the makeup of its share registry. … With a market capitalization of CHF21b, Lonza Group is rather large. … We'd expect to see institutional investors on the register.
Simply Wall St - – Full articleDoes Lonza Group Ltd (VTX:LONN) Have A Good P/E Ratio?
To keep it practical, we'll show how Lonza Group Ltd's (VTX:LONN) P/E ratio could help you assess the value on offer. … How Do I Calculate Lonza Group's Price To Earnings Ratio … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleCompany Info
Description
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system. The company’s products and services also cover pharma and biotech solutions, such as bioprocess systems, drug discovery, endotoxin detection, informatics, bioassay services, and encapsulation technologies; consumer health solutions comprising hygiene, nutrition, personal care, preservation, and capsules and food supplements; and agro ingredients, such as intermediates, molluscicides, specialties, formulation ingredients, crop protection, and animal care solutions. In addition, its products and services include coatings and composites, performance intermediates, composite materials, and functional chemicals; and materials protection, oil and gas, marine antifouling, hydrazine, and wood protection solutions. The company serves pharmaceutical, biotech, consumer health, nutrition, and specialty chemicals and industrial markets. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Details
| Name: | Lonza Group Ltd |
| LONN | |
| Exchange: | SWX |
| Founded: | 1897 |
| CHF24,850,188,747 | |
| 74,246,157 | |
| Website: | http://www.lonza.com |
| Address: |
Lonza Group Ltd Muenchensteinerstrasse 38, Basel, Basel-Stadt, 4002, Switzerland |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| SWX | LONN | Registered Shares | SIX Swiss Exchange | CH | CHF | 01. Nov 1999 | |
| OTCPK | LZAG.F | Registered Shares | Pink Sheets LLC | US | USD | 01. Nov 1999 | |
| DB | LO3 | Registered Shares | Deutsche Boerse AG | DE | EUR | 01. Nov 1999 | |
| LSE | 0QNO | Registered Shares | London Stock Exchange | GB | CHF | 01. Nov 1999 | |
| BATS-CHIXE | LONNZ | Registered Shares | BATS 'Chi-X Europe' | GB | CHF | 01. Nov 1999 | |
| OTCPK | LZAG.Y | UNSPONSORED ADR | Pink Sheets LLC | US | USD | 13. Oct 2008 |
Number of employees
Current staff
Industry
| Life Sciences Tools and Services | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/19 20:46 |
| End of day share price update: | 2019/06/19 00:00 |
| Last estimates confirmation: | 2019/06/11 |
| Last earnings filing: | 2019/03/07 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
